

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT

**THE PFO OCCLUDER SYSTEM OMNISEAL SUCCESSFULLY
COMPLETED THE FIRST CLINICAL IMPLANTATION**

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that the first clinical implantation of OmniSeal, a PFO occluder system developed by Ningbo Diochange Medical Technology Co., Ltd. (寧波迪創醫療科技有限公司) (“**Diochange Medical**”), a wholly-owned subsidiary of the Company, has recently been successfully completed.

OmniSeal has a number of advantages from its innovative design. Its unique fully puncturable design enables secondary intervention in the left heart system. OmniSeal can adapt to different anatomical structures and shapes of patent foramen ovale, which reduces post-operation complications such as arrhythmias and atrial fibrillation. While ensuring effective occlusion, it also reduces residual shunt and the risk of blood clots.

The successful completion of the first clinical implantation of OmniSeal has proven the design advantages of OmniSeal and marked a new stage of the Company’s products for patent foramen ovale diseases. OmniSeal is also the third innovative product of Diochange Medical entering clinical trial following its left atrial appendage occluder and interatrial shunt. The Company will continue to develop innovative products and implement a more holistic plan of commercialization for structural heart diseases so as to provide a complete solution for the majority of patients with structural heart diseases.

Cautionary Statement: There is no assurance that we will ultimately develop, market and/or commercialize OmniSeal successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, January 3, 2024

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.